French Company Gets FDA Breakthrough Status For Brain Device
The US FDA has designated Carthera’s SonoCloud-9 as a breakthrough device. The French company’s ultrasound technology is designed to treat a wide range of brain diseases, including recurrent glioblastoma.
You may also be interested in...
CarThera has secured its first financial round from institutional investors to launch a pivotal trial evaluating the company's Sonocloud ultrasound therapy for patients with recurrent glioblastoma.
The US FDA has granted its breakthrough designation to a virtual reality therapy that recreates everyday scenarios for patients dealing with severe anxiety and schizophrenia.
The US House of Representatives overwhelmingly passed legislation authorizing the creation of a federal health agency to advance biomedical research. The bill now goes to the Senate.